Inactief instrument

Andere talen Cellectar Biosciences Inc Nasdaq

Aandelen

US15117F2039

slotkoers Nasdaq Andere beurzen
- ^USD	-

29/05	Cellectar Biosciences, Inc. en City of Hope Cancer Center gaan samenwerking aan voor de evaluatie van Iopofosine I 131 in Mycosis fungoides	CI
14/05	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides	29/05
Cellectar Biosciences, Inc. and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis fungoides	29/05
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update	14/05
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day	08/05
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024	07/05
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update	27/03
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024	20/03
Cellectar Biosciences : Corporate Presentation - March 2024	18/03
Cellectar Biosciences to Present at the 36th Annual Roth Conference	14/03
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study	30/01
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study	30/01
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million	25/01
Cellectar Biosciences Reports Complete Central Nervous System Clearance in Relapsed, Refractory Waldenstrom's Macroglobulinemia Patient	23/01
Sector Update: Health Care Stocks Advance Late Afternoon	22/01
Cellectar Biosciences Shares Rise as Drug Shows Promise on Complete Central Nervous System Clearance on Cancer Type	22/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cellectar Biosciences Inc Nasdaq

Aandelen

US15117F2039

Andere talen

Filters